Abstract Candida infection among multiple sclerosis (MS) patients has not been studied in depth. We determined whether there is an association between serological evidence of Candida infection and MS. Blood specimens were obtained from 80 MS patients and 240 matched controls. Immunofluorescence analysis and ELISA were used to detect Candida species antibodies and slot-blot to detect antigens. Using immunofluorescence analysis, moderate to high concentrations of serum antibodies to Candida famata were present in 30 (37.5%) MS patients vs. 30 (12.5%) controls (p<0.001). Results for Candida albicans were 47.5% (38/80) in MS patients vs. 21.3% (51/240) in controls (p<0.001), for Candida parapsilosis 37% (28/80) vs. 17.1% (41/240) (p<0.001) and for Candida glabrata 46.3% (37/80) vs. 17.5% (42/240) (p<0.001), respectively. After adjusting for age and gender, the odds ratios (95% confidence intervals) for MS, according to the presence of Candida antigens were: 2.8 (0.3-23.1, p =0.337) for Candida famata; 1.5 (0.7-3.4, p=0.290) for Candida albicans; 7.3 (3.2-16.6, p<0.001) for Candida parapsilosis; and 3.0 (1.5-6.1, p=0.002) for Candida glabrata. The results were similar after excluding ten patients on immunosuppressants. The results of this single study suggest that Candida species infection may be associated with increased odds of MS.
Introduction
Multiple sclerosis (MS) is one of the most common chronic neurological disorders among young adults, especially in high northern latitudes, and the most common cause of non-trauma related disability in this age group [1] . The broad spectrum of symptoms of MS considerably impact upon the quality of life experienced by patients and their families to a greater extent than several other chronic diseases [2] [3] [4] [5] [6] . Although etiological factors are not clearly established, there are data which suggest that non-genetic environmental factors, especially infectious agents, e.g. virus or Chlamydia pneumoniae may play a role in MS [7] [8] [9] [10] . Among these, Epstein-Barr virus (EBV) stands out as one of the most consistent risk factors [10] . Nevertheless, some features of MS epidemiology are not explained by EBV and strongly suggest a key role of other infectious agents [9] . For instance, Butcher [11] had suggested a global correlation between MS incidence and milk consumption, as taken from data provided by the Food and Agriculture Organization of the United Nations (FAO). In addition, in an analysis of 27 countries and 29 populations worldwide, Malosse et al. [12] found a good correlation (rho=0.836) between MS prevalence and fresh cow milk consumption. Milk may contain potentially pathogenic yeast species such as Candida parapsilosis or Candida glabrata, both able to grow at 40°C [13] .
In 1993, Gass [14] described a new syndrome, the socalled acute zonal occult outer retinopathy (AZOOR) in 13 patients who were predominantly young women. This enigmatic syndrome is characterized by rapid loss of one or more large zones of outer retinal function, photopsia, minimal fundoscopic changes, and electroretinographic abnormalities affecting one or both eyes [14] . Recent evidence from case reports and case series suggest a link between AZOOR and MS [15, 16] . The only available long-term follow-up study of patients with AZOOR showed the presence of white matter abnormalities on cerebral magnetic resonance imaging in a substantial subgroup [15] . Both AZOOR and MS share common characteristics, such as a relapsing course, often followed by gradual worsening, a skew to female sex, inflammatory lesions localized predominantly in areas around venules, along with signs of secondary neuronal cell loss [14] [15] [16] . Moreover, for both AZOOR and MS, there seems to be an association with generalized autoimmune disorders [14] [15] [16] . In the last three years, an association between AZOOR and Candida species infection has been suggested [17] [18] [19] .
Although pathogenic yeasts from the genus Candida are well recognized infectious agents [20, 21] , they have never been systematically studied in MS. Demyelinated lesions in the central nervous system have been described in patients with Candida infection [22] . The previous associations encouraged us to test the hypothesis that some yeast species of medical importance (including Candida famata, Candida albicans, Candida parapsilosis, and Candida glabrata) are associated with MS. Traditional methods of Candida species detection, which include blood culture and biopsy, usually lack both sensitivity and specificity. Therefore, diverse non-culture-based methods were also applied in the current study [23] .
Methods

Study population
MS patients were included in the study if they had met the McDonald criteria [24] . Exclusion criteria included antibiotic therapy within the previous six months, any corticosteroid therapy within the previous 12 months, and major systemic conditions (including hematologic or solid-organ malignancies, recent surgery, gastrointestinal tract surgery, endocrinopathies, and acute or chronic renal failure).
Our sample of patients with MS was derived from the MS association of Madrid (Spain). This association was chosen because (a) there was a close relationship between our research group and the association and (b) the association maintained a computer-based registry of MS patients from the community of Madrid. In this computerbased registry, basic demographic data of the members (e.g. age and gender) were recorded. We obtained permission from the association to access this confidential information. The association included more than 1,000 MS patients from the community of Madrid (Spain). We recruited MS patients without regard to age or gender or other demographic factors (i.e. every fifth name was selected from patient lists so as to achieve the needed number of recruits) from the MS association. MS patients were recruited between June 2007 and May 2008.
A 20-minute interview was conducted on each MS patient in which information on age of MS onset and disease evolution was also obtained. Three neurologists with expertise in MS (JBL, PC, and MDS) participated in the clinical assessment and applied the EDSS scale to rate the severity of disease (range = 0-10) [25] . Three subgroups were formed according to EDSS score: low physical disability (EDSS 0-2.5); moderate physical disability (EDSS 3.0-5.5); and high physical disability (EDSS ≥6.0).
Healthy controls were selected from those subjects who were occasional blood donors at different health centers in Madrid (Spain) between June 2007 and May 2008. MS patients were 1:3 frequency-matched with control subjects. Frequency matching was based on age (±5 years) and gender. Control subjects were excluded if they had symptoms or a history of a major systemic disease or MS, and none was being treated with any type of antibiotics.
A 10-ml venous blood sample was obtained from each individual. In the case of MS patients, blood samples were obtained just after clinical assessment. In all analyses, control samples were interspersed with samples from patients. Laboratory studies (see below) were performed by experienced scientists (DP, RA and LC) who were blinded to the diagnosis (patient vs. control). This study was approved by both the research ethics board at University Hospital "12 de Octubre" and at the Autónoma University of Madrid. Signed consent was obtained for all participants.
Candida infection detection
Candida species growth
All the blood samples were cultured for yeasts in a YEPD medium (1% yeast extract, 2% peptone, and 2% glucose) by incubation at 30°C. The same medium, containing agar, was used to test growth of individual yeast colonies.
Antibodies detection
Rabbit antisera against different yeast species were obtained by inoculation of 0.5 ml phosphate-buffered saline (PBS) containing 1 or 2 mg yeast after autoclaving and lyophilization. Each inoculum had been mixed previously with the same volume of Freund's adjuvant. Rabbits were inoculated up to four times and the antibody titre and specificity of the sera were tested by indirect immunofluorescence and enzyme-linked immunosorbent assay (ELISA).
Indirect immunofluorescence For Candida famata, 1 ml of culture was placed in 1.5-ml microcentrifuge tubes. Cells were washed with PBS, incubated with 50 mM ammonium chloride for 10 min, and washed three times with PBSTween 20. Cells were then treated with the different serum samples diluted 1:500 in PBS-Tween 20 at 37°C for 2 hours, washed again with PBS-Tween 20, and incubated with the secondary antibody. Rabbit anti-human fluoresceinconjugated antibody (immunoglobulin A [IgA] plus IgM plus IgG) was added at a dilution of 1:500. The samples were incubated at 37°C for another hour. The cells were then washed, resuspended in PBS, and mounted on slides with a drop of Depex (Serva). For the remaining Candida species, an Euroimmun commercial kit (Medizinische Labordiagnostika AG) was used in accordance with the manufacturer's instructions and using the same serum dilutions as for Candida famata [17] [18] [19] . Finally, the cells were observed under a fluorescence microscope [17] [18] [19] .
Positivity percentage of each one of the results was compared to the positive control provided by the manufacturer (Euroimmune, Germany). Results were scored as follows: 0% (clearly negative in contrast with the positive control provided by the manufacturer), 20% (low antibody concentrations), 40% and 60% (moderate antibody concentrations), 80% and 100% (clearly positive as the positive control provided by the manufacturer) [17] [18] [19] .
Enzyme-linked immunosorbent assay (ELISA) ELISA was carried out as described previously [17, 18] . Briefly, yeast suspension diluted in PBS was seeded in ELISA microtitre plates (Maxisorp; Nunc A/S, Denmark). The plates were blocked with PBS containing 3% low-fat dried milk and 0.2 % Tween 20. Sera from the study participants were added at different dilutions and the value obtained at 1:500 dilution was selected for data analysis. Plates were subsequently incubated with goat anti-human (heavy and light chain) Ig horseradish peroxidase-conjugated antibodies (Pierce) and washed five times. Colour development was accomplished by incubation with o-phenylenediamine (Sigma) and measured at 490 nm in a microplate reader (EL340; Bio-Tek Instruments). Results were scored as absolute values [17, 18] .
Antigen detection
The presence of Candida species antigens in plasma was determined by slot-blot analyses [18] . Different serum dilutions (200 μl) in TBS were added to each well. Samples were blotted onto a 45 mm nitrocellulose membrane (BioRad) previously hydrated in TBS for 10 min using a BioDot SF apparatus (Bio-Rad). After blotting, the membrane was processed and developed. The primary rabbit polyclonal antibodies against Candida famata, Candida albicans, Candida parapsilopsis and Candida glabrata were used at a 1:1000 dilution. A donkey anti-rabbit IgG horseradish peroxidase-conjugated antibody (Amersham Biosciences) at a 1:5000 dilution was used as secondary antibody [18] . Titres ≥20 were counted positive and ≤19, counted negative or doubtful [18, 19] .
Data analysis and sample size
Statistical analyses were performed in SPSS Version 15.0 (SPSS, Inc., Chicago, IL). All tests were two-sided, and significance was accepted at the 5% level (alpha=0.05). The continuous variables age and ELISA were not normally distributed, and thus Mann-Whitney test was used to calculate differences between the patients and controls. Chi-square was used for categorical data (gender, immunofluorescence and slot-blot analyses). Spearman's correlation coefficient was used to determine the correlations between the clinical and serological parameters. Odds ratios (ORs) and 95% confidence intervals (CIs) assessing the risk of MS associated with infection by each type of Candida, using indirect immunofluorescence and slot-blot, were estimated by use of binary logistic regression, adjusted for age and gender.
The targeted sample size (80 participants in the patient group and 240 participants in the control group) had 100% power to detect a 30% difference in slot-blot analyses between patients and controls (assuming alpha=0.05).
Results
Of 85 eligible patients with MS, five (5.9%) were excluded due to insufficient volume of blood drawn. None were excluded because they had major comorbidities or had received antibiotic or corticosteroid therapy. The final study sample consisted of 80 patients with MS and 240 controls who were frequency-matched by age and gender. Forty (50%) MS patients were taking immunomodulatory (betainterferons and glatiramer acetate) or immunosuppressant (azathioprine, methotrexate and mitoxantrone) medications (Table 1 ). The remaining 33 (41.25%) had never been on immunomodulatory or immunosuppressant medications or their drugs had been withdrawn due to inefficacy at least one year before clinical assessment (7/80, 8.75%). The patients with MS and controls were similar in age and gender (Table 2) . Disease duration ranged from 1 to 39 years (median = 10.5 years) ( Table 1) . No yeasts were cultured from the blood samples of patients and controls.
Moderate to high concentrations of serum antibodies to Candida famata were present in 30 (37.5%) MS patients vs. 30 (12.5%) controls (p<0.001), using indirect immunofluorescence analysis (Table 2) . In a regression analysis that adjusted for age and gender, subjects with moderate to high antibody concentrations were more than four times more likely to have MS than were those with negative or low concentrations of antibodies (OR 4.4, 95% CI 2.4-8.1, p< 0.001) (Table 3) . However, the median concentrations of antibodies using ELISA were similar in the group of patients with MS compared with the control group (0.5±0. Tables 3 and 4) . No correlations were found between the clinical and the serological parameters with any type of Candida species. The above results were also similar after excluding ten MS patients who were on immunosuppressant therapies or after excluding 47 MS patients who were receiving (40 cases) or ever received (seven cases) immunosuppressant or immunomodulatory therapies (data not shown). In addition, after excluding 40 MS patients whose MS duration was >10 years, the results remained similar (data not shown).
Discussion
Several Candida species are widely distributed throughout the human population as both commensal organisms and as intermittent pathogens [26, 27] . In the clinical arena, blood cultures are the main assay for routine detection of candidiasis [26] . However, microbiological confirmation is difficult because blood cultures can be negative in up to 50% of autopsy-proven cases of deep-seated candidiasis or may only become positive late in the infection [26] . Thus, different approaches are needed to demonstrate disseminated fungal infection. Given the lack of a single definitive test to detect Candida species, different assays were carried out in our study. These included, first, a search for antibodies against Candida species in blood by means of immunofluorescence and ELISA tests, and second, detection of Candida species proteins in blood by means of slot-blot analyses [17] [18] [19] .
To our knowledge, this is the first large epidemiologic study to test for an association between MS and infection with Candida species. In this case-control study we found a significant association between elevated antibodies of four species of Candida and MS using indirect immunofluorescence. However, these differences were not observed using ELISA, but for Candida glabrata. We feel detection of antibodies by ELISA in this large sample of participants showed poor specificity. Although it is true that antibodies to Candida species may occur in normal individuals as a result of commensal colonization of several anatomically distinct sites including skin, oral, gastrointestinal tract, and vagina [27, 28] , MS patients had a significant seroprevalence of Candida species using indirect immunofluorescence. However, the most striking result of our study is a near-complete (91.3%) presence of Candida parapsilosis antigens in patients with MS compared with only 59.2% of subjects in the control group. Subjects with positivity for Candida parapsilosis antigens were seven times more likely to have MS than were those with negative or doubtful concentrations of antigens. The basis for the case-control differences we observed is not clear. The prevalence hypothesis, proposed by Kurtzke [29] , suggests that MS is caused by a pathogen, which may be more common in regions of high MS prevalence. This pathogen would be widespread and, in most individuals, would cause an asymptomatic persistent infection and, only rarely and years after the primary infection, would this agent cause MS. Milk consumption has been correlated with higher worldwide prevalence rates of MS [11, 12] , and pathogenic Candida species may be isolated from milk products [13] . One could hypothesize that chronic or reactivated latent infection by pathogenic Candida species drives or initiates autoimmunity. However, longitudinal studies of incident MS patients are required to assess whether the observed associations are due to a pathogenic effect of Candida species on the risk of developing incident MS or a susceptibility on the part of patients with MS to be infected by yeasts. We acknowledge several limitations of this study. First, we recruited a group of patients with MS (i.e. patients seen in a patient-based association) and, as a consequence, our results might not be generalized to population-dwelling MS patients. Therefore, we acknowledge the need to replicate these findings in a population-based survey of unselected patients. Second, while we frequency-matched patients and controls based on age and gender we were not able to adjust for other potential unmeasured confounders, such as socioeconomic status, dietary intakes or hygiene habits. Third, there is also evidence that immunosuppressant therapies could interfere with the generation of antibodies [30] . However, after excluding ten MS patients who were receiving immunosuppressant therapies, the concentrations of Candida species antibodies remained significantly higher in MS patients than controls. Fourth, therapeutic use of repeated injectable beta-interferons or glatiramer acetate (immunomodulatory therapies) may prone to skin colonization by Candida species that could be followed by candidemia. However, the results were similar after excluding 47 MS patients who were receiving (40 cases) or ever received (7 cases) immunosuppressant or immunomodulatory therapies. In addition, we enrolled 40 MS patients whose MS duration was >10 years. Patients with long-lasting disease duration (>10 years) may be exposed to corticosteroids or they could have a higher frequency of urinary tract infections and hence antibiotic treatment. However, the results were similar after excluding these 40 MS patients whose MS duration was longer than 10 years. This supports that the reported association is present early in the MS course.
In summary, the results of this single study suggest that Candida species infection may be associated with increased odds of MS. The clinical importance of this association is uncertain. We therefore propose future studies that should clarify whether and, if so, how yeasts from the genus Candida act in the pathogenesis of this disease.
